Ontology highlight
ABSTRACT: Background
Budesonide foam, a rectally administered, second-generation corticosteroid with extensive hepatic first-pass metabolism, is efficacious for the treatment of mild-to-moderate ulcerative proctitis and ulcerative proctosigmoiditis.Aim
The aim of this study was to comprehensively assess the safety and pharmacokinetic profile of budesonide foam.Methods
Data from five phase III studies were pooled to further evaluate safety, including an open-label study (once-daily treatment for 8 weeks), an active-comparator study (once-daily treatment for 4 weeks), and two placebo-controlled studies and an open-label extension study (twice-daily treatment for 2 weeks, then once daily for 4 weeks). Data from the placebo-controlled studies and two phase I studies (i.e., patien
SUBMITTER: Rubin DT
PROVIDER: S-EPMC4621699 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature